Evolus, Inc. Common Stock (EOLS) Stock Price

EOLSStock

$7.10+12.70%52W

Market Cap$468.96M

P/E—

PEG Ratio—

Div yield—

Beta1.37

EOLS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)50.00%

Price vs S&P 500 (4W)-9.81%

VGM Score63.86

Book Value / Share (Quarterly)$0.09

P/TBV (Annual)11.56x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)25.99%

Cash Flow / Share (Quarterly)$-0.33

Price vs S&P 500 (YTD)-5.16%

Gross Margin (TTM)66.74%

Net Profit Margin (TTM)-10.85%

EPS (TTM)$-0.53

10-Day Avg Trading Volume0.79M

EPS Excl Extra (TTM)$-0.53

Revenue Growth (5Y)39.38%

EPS (Annual)$-0.80

ROI (Annual)-39.69%

Gross Margin (Annual)66.33%

Net Profit Margin (5Y Avg)-32.77%

Cash / Share (Quarterly)$0.68

Revenue Growth QoQ (YoY)21.18%

ROA (Last FY)-22.86%

Revenue Growth TTM (YoY)13.87%

EBITD / Share (TTM)$-0.19

ROE (5Y Avg)-308.23%

Operating Margin (TTM)-5.90%

Cash Flow / Share (Annual)$-0.78

P/B Ratio84.93x

P/B Ratio (Quarterly)126.60x

Net Income / Employee (Annual)$-154,600

EV / Revenue (TTM)1.83x

Net Interest Coverage (TTM)-1.87x

ROA (TTM)-15.03%

EPS Incl Extra (Annual)$-0.80

Current Ratio (Annual)1.90x

Quick Ratio (Quarterly)1.24x

3-Month Avg Trading Volume0.87M

52-Week Price Return12.70%

Revenue / Employee (TTM)$947,600

Tangible BV / Share (Quarterly)$0.31

P/S Ratio (Annual)1.58x

Asset Turnover (Annual)1.32x

52-Week High$9.31

Operating Margin (5Y Avg)-27.55%

EPS Excl Extra (Annual)$-0.80

CapEx CAGR (5Y)21.90%

26-Week Price Return59.91%

Quick Ratio (Annual)1.49x

13-Week Price Return23.91%

Total Debt / Equity (Annual)22.00x

Current Ratio (Quarterly)1.70x

Enterprise Value$580.53M

Revenue / Share Growth (5Y)22.42%

Asset Turnover (TTM)1.39x

Revenue / Employee (Annual)$889,700

Inventory Turnover (Annual)5.12x

Pretax Margin (Annual)-17.15%

Cash / Share (Annual)$0.83

3-Month Return Std Dev64.23%

Gross Margin (5Y Avg)64.30%

Net Income / Employee (TTM)$-102,800

ROE (Last FY)-913.07%

Net Interest Coverage (Annual)-1.26x

EPS Basic Excl Extra (Annual)$-0.80

P/FCF (TTM)43.99x

Receivables Turnover (TTM)5.75x

Total Debt / Equity (Quarterly)22.00x

EPS Incl Extra (TTM)$-0.53

Receivables Turnover (Annual)5.81x

ROI (TTM)-37.81%

P/S Ratio (TTM)1.48x

Pretax Margin (5Y Avg)-32.64%

Revenue / Share (Annual)$4.61

Tangible BV / Share (Annual)$0.56

Forward P/E52.64x

Price vs S&P 500 (52W)-2.83%

Year-to-Date Return6.77%

5-Day Price Return-8.39%

EPS Normalized (Annual)$-0.80

ROA (5Y Avg)-27.43%

Net Profit Margin (Annual)-17.38%

Month-to-Date Return-11.25%

Cash Flow / Share (TTM)$-1.03

EBITD / Share (Annual)$-0.41

Operating Margin (Annual)-10.99%

LT Debt / Equity (Annual)22.00x

ROI (5Y Avg)-50.30%

LT Debt / Equity (Quarterly)22.00x

EPS Basic Excl Extra (TTM)$-0.53

P/TBV (Quarterly)36.12x

P/B Ratio (Annual)126.60x

Inventory Turnover (TTM)3.13x

Pretax Margin (TTM)-10.64%

Book Value / Share (Annual)$0.09

Price vs S&P 500 (13W)21.22%

Beta1.37x

Revenue / Share (TTM)$4.80

ROE (TTM)-410.18%

52-Week Low$3.86

vGradeC

gGradeB

mGradeB

vgmGradeB

EOLS Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	-$0.04	-$0.02	+52.62%(+$0.02)
Q1 2026	May 4, 2026	-$0.12	-$0.05	+57.87%(+$0.07)
Q4 2025	Mar 3, 2026	$0.04	$0.01	-64.80%(-$0.02)
Q3 2025	Nov 5, 2025	-$0.18	-$0.15	+19.38%(+$0.04)
Q2 2025	Aug 5, 2025	-$0.09	-$0.26	-175.05%(-$0.16)

EOLS Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.23

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
EOLSEvolus, Inc. Common Stock	C	B	B	1.5x	13.9%	66.7%	—	$7.10
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Evolus, Inc. Common Stock

Evolus Inc commercializes Jeuveau, a purified botulinum toxin formulation used to treat moderate to severe frown lines. The company generates revenue from product sales in the United States and Europe, and from distribution partnerships in Canada. Evolus operates in the self-pay aesthetic market, targeting physicians and consumers seeking non-invasive cosmetic treatments.

EOLS Next Earnings Report

Report dateNov 4, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.07

Revenue estimate$77.58M

Also reporting on Nov 4, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

EOLS Insider Transactions

SellSep 2, 2026
MOATAZEDI DAVID
Chief Executive Officer
Shares: 105,108Value: $950,019

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

TROXTRONOX LIMITED CL A ORDINARY SHARESIndustrial Chemicals
ETRAElectra Therapeutics, Inc. Common stockBiological Products
VALNValneva SE American Depositary SharesBiological Products
PROKProKidney Corp. Class A Ordinary SharesBiological Products
ENTXEntera Bio Ltd. Ordinary SharesBiological Products
LXFRLuxfer Holdings PLC Ordinary SharesIndustrial Chemicals
RGNXREGENXBIO Inc.Biological Products
ALLOAllogene Therapeutics, Inc. Common StockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.2

Strong Buy

Consensus rating

52-Week Range

Low$3.86

High$9.31